Product Information
ADZENYS XR-ODT 3.1 MG TABLET is a brand product labeled by Neos Therapeutics Brands, LLC, priced at $19.2046 per EA under NDC 70165000530. Its NADAC has been published 472 times since Sep 20, 2017.
FDA first approved this application on Jan 27, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3.1 mg/1
Manufacturer
Neos Therapeutics Brands, LLCNDC
70165000530
Classification
Brand
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMPHETAMINEApproval Type
New Drug (NDA)
FDA Application
NDA204326FDA Approved
1/27/2016
TE Code
AB
On Market Since
2/16/2016
Pharmacological Classes
Price Statistics
The NADAC for ADZENYS XR-ODT 3.1 MG TABLET has been published 472 times since Sep 20, 2017, and over the history we have for it it has risen 104.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $19.2046 per EA |
|---|---|
| All-time high | $19.3843 (Mar 11, 2026) |
| All-time low | $9.3844 (Sep 20, 2017) |
| 52-week high | $19.3843 |
| 52-week low | $19.2046 |
| Median price | $14.0004 |
| Average price | $14.0574 |
| Largest weekly change | +14.9% (Aug 13, 2025) |
| Weeks tracked | 472 |
| Tracking since | Sep 20, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Amphetamine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Neos Therapeutics Brands, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amphetamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ADZENYS XR-ODT 3.1 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ADZENYS XR-ODT 3.1 MG TABLET, manufactured by Neos Therapeutics Brands, LLC, is $19.2046 per EA (NDC 70165000530), effective Sep 30, 2026.
How has the price of ADZENYS XR-ODT 3.1 MG TABLET changed over time?
Over the history we have for it, the NADAC for ADZENYS XR-ODT 3.1 MG TABLET has risen 104.6%. It has been tracked across 472 weekly CMS publications since Sep 20, 2017.
What are the highest and lowest recorded NADAC prices for ADZENYS XR-ODT 3.1 MG TABLET?
Since Sep 20, 2017, the NADAC for ADZENYS XR-ODT 3.1 MG TABLET has ranged from a low of $9.3844 (Sep 20, 2017) to a high of $19.3843 (Mar 11, 2026), with a median of $14.0004 per EA.
Are there cheaper alternatives to ADZENYS XR-ODT 3.1 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ADZENYS XR-ODT 3.1 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ADZENYS XR-ODT 3.1 MG TABLET?
ADZENYS XR-ODT 3.1 MG TABLET (NDC 70165000530) is labeled by Neos Therapeutics Brands, LLC, and CMS classifies it as a brand product.